Abstract: Methods, devices, and computer-readable storage media are disclosed. In an example method, segmentation of to-be-encoded information bits of a length N into respective quantities of different types of segments is performed. The different types of segments are among (b?a+1) types of segments that correspond to (b?a+1) different segment code lengths. The (b?a+1) types of segments comprise a minimum-length segment that has the minimum segment code length of 2{circumflex over (?)}a and a maximum-length segment that has the maximum segment code length of 2{circumflex over (?)}b. The respective quantities of the different types of segments are determined based on the length N and a code rate in an orderly manner, wherein the orderly manner comprises firstly determining a quantity of the maximum-length segments and lastly determining a quantity of the minimum-length segments. Polar code encoding is performed on the respective quantities of the different types of segments of the to-be-encoded information bits.

Abstract: An encoding method, a decoding method, and an apparatus. A symbol quantity S is determined based on an encoding bit quantity L and an energy level quantity B, where S is S1 or S2, S1=L/B, and S2=L/2B. K information sub-channels are determined from an encoding sequence based on the symbol quantity S, the energy level quantity B, and a reliability sequence. K information bits are encoded and a bit sequence is output based on the K information sub-channels, where the K information sub-channels are selected from candidate sub-channels based on an order of reliability of the candidate sub-channels. The candidate sub-channels are S1 sub-channels or 2×S2 sub-channels in a sub-sequence whose energy level is i in the encoding sequence.

Abstract: A polar code construction method and an apparatus. A communication apparatus obtains a reliability weight sequence, and determines a first threshold that indicates a weight of lowest reliability of a subchannel corresponding to an information bit. The communication apparatus determines a non-pre-frozen subchannel corresponding to a content value greater than or equal to the first threshold in the reliability weight sequence as the subchannel corresponding to the information bit based on the first threshold, and performs polar coding on the information bit based on the subchannel corresponding to the information bit.

Abstract: An information transmission method and an apparatus. The information transmission method includes: a receive end sends first indication information, where the first indication information indicates a target receiving mode of the receive end, and the target receiving mode is one of a plurality of receiving modes. The receive end receives service information based on the target receiving mode. The receive end performs decoding processing on the service information based on the target receiving mode. In this way, power consumption can be further reduced, and information transmission of a plurality of service types can be supported, thereby improving information transmission flexibility and user experience.

Abstract: Embodiment techniques map parity bits to sub-channels based on their row weights. In one example, an embodiment technique includes polar encoding, with an encoder of the device, information bits and at least one parity bit using the polar code to obtain encoded data, and transmitting the encoded data to another device. The polar code comprises a plurality of sub-channels. The at least one parity bit being placed in at least one of the plurality of sub-channels. The at least one sub-channel is selected from the plurality of sub-channels based on a weight parameter.

Abstract: The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.

Abstract: Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Abstract: Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Abstract: Methods for efficient preparation of drug-polymer (or oligomer) conjugates useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications are provided. The invention also provides nanoparticles prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug). The method is particularly useful for formation of polymer/oligomer conjugates with drugs and other chemical species containing one or more hydroxyl groups or thiol groups.

Abstract: The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.

Abstract: The invention provides a drug-polymer nanoconjugate that includes a drug covalently bonded to a polymer. The nanoconjugate can include a block copolymer coating and/or an albumin coating. The drug of the drug-polymer nanoconjugate can be one or more of a variety of therapeutic agents linked to the polymer through ether or thioether linkages formed from hydroxyl or thiol groups of the drug. The albumin coating can substantially or completely retard or prevent aggregation of the nanoconjugates in solid form or in solution. The invention further provides compositions that include a plurality of drug-polymer nanoconjugates, as well as methods for using the drug-polymer nanoconjugates, such as in therapeutic or diagnostic applications.

Abstract: Methods for efficient preparation of drug-polymer (or oligomer) conjugates useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications are provided. The invention also provides nanoparticles prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug). The method is particularly useful for formation of polymer/oligomer conjugates with drugs and other chemical species containing one or more hydroxyl groups or thiol groups.

Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

Abstract: A method for executing a fully mixed initiative dialogue (FMID) interaction between a human and a machine, a dialogue system for a FMID interaction between a human and a machine and a computer readable data storage medium having stored thereon computer code for instructing a computer processor to execute a method for executing a FMID interaction between a human and a machine are provided. The method includes retrieving a predefined grammar setting out parameters for the interaction; receiving a voice input; analyzing the grammar to dynamically derive one or more semantic combinations based on the parameters; obtaining semantic content by performing voice recognition on the voice input; and assigning the semantic content as fulfilling the one or more semantic combinations.

Abstract: The invention provides a drug-polymer nanoconjugate that includes a drug covalently bonded to a polymer. The nanoconjugate can include a block copolymer coating and/or an albumin coating. The drug of the drug-polymer nanoconjugate can be one or more of a variety of therapeutic agents linked to the polymer through ether or thioether linkages formed from hydroxyl or thiol groups of the drug. The albumin coating can substantially or completely retard or prevent aggregation of the nanoconjugates in solid form or in solution. The invention further provides compositions that include a plurality of drug-polymer nanoconjugates, as well as methods for using the drug-polymer nanoconjugates, such as in therapeutic or diagnostic applications.

Abstract: A noise processing device and its method are provided for a video/audio system having a high definition multimedia interface (HDMI). The noise processing device includes a detecting unit, a signal generating unit, and a decision unit. The noise processing method includes using the detecting unit to monitor a variation related to an audio signal and generate a detecting signal accordingly; using the signal generating unit to produce an adjustment signal according to the detecting signal; and using the decision unit to produce an output audio signal according to the audio signal and the adjustment signal. Another embodiment of the noise processing device includes a compensation tracking unit having a control unit. The compensation tracking unit produces an output audio signal according to a difference between the output audio signal itself and the audio signal and a gain of the control unit.

Abstract: The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.

Abstract: A method for executing a fully mixed initiative dialogue (FMID) interaction between a human and a machine, a dialogue system for a FMID interaction between a human and a machine and a computer readable data storage medium having stored thereon computer code for instructing a computer processor to execute a method for executing a FMID interaction between a human and a machine are provided. The method includes retrieving a predefined grammar setting out parameters for the interaction; receiving a voice input; analysing the grammar to dynamically derive one or more semantic combinations based on the parameters; obtaining semantic content by performing voice recognition on the voice input; and assigning the semantic content as fulfilling the one or more semantic combinations.

Abstract: A method for converting a frame rate of a video signal comprising a data enable signal by means of a first buffer and a second buffer is disclosed. The method comprises: alternatively accessing the first buffer and the second buffer according to a first frame rate; determining an accessing time point of the first and the second buffers according to the data enable signal; and accessing the buffer, which is one of the first and the second buffers and not accessed at the accessing time point, according to a second frame rate, wherein the second frame rate is faster than the first frame rate.

Abstract: Methods for efficient preparation of drug-polymer (or oligomer) conjugates which are useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications. The invention additionally provides certain drug-polymer and drug-oligomer conjugates which are useful in the preparation of particles for delivery of the drug in vivo. The invention also provides nanoparticles of this invention prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug).